Current Report Filing (8-k)
September 03 2015 - 9:13AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date
of earliest event reported): September 3, 2015
|
ORAMED PHARMACEUTICALS INC. |
(Exact name of registrant as specified in its charter) |
DELAWARE |
|
001-35813 |
|
98-0376008 |
(State or Other Jurisdiction |
|
(Commission |
|
(IRS Employer |
of Incorporation) |
|
File Number) |
|
Identification No.) |
Hi-Tech Park 2/4 Givat Ram, PO Box 39098, Jerusalem, Israel |
|
91390 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
+972-2-566-0001
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
On September 3, 2015, Oramed Pharmaceuticals Inc. (the “Company”),
and its wholly-owned subsidiary (the “Subsidiary”), agreed to extend for 45 days the no-shop period contained in the
non-binding Letter of Intent (“LOI”) that was signed with Sinopharm Capital Management Co. Ltd. and Hefei Life Science
& Technology Park Investments and Development Co., Ltd. (together, “Sinopharm-HLST”) on July 3, 2015. The 45 day
extension is intended to allow sufficient time for the parties to conclude the definitive agreements.
Warning Concerning Forward Looking Statements
This Current Report on Form 8-K
contains statements which constitute forward looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and other securities laws. These forward looking statements are based upon the Company’s present
intent, beliefs or expectations, but forward looking statements are not guaranteed to occur and may not occur for various
reasons, including some reasons which are beyond the Company’s control. For example, this Report states that the 45
days extension of the LOI with Sinopharm-HLST is intended to allow sufficient time for the conclusion of definitive
agreements between the parties. However, the LOI is non-binding and subject to negotiation; accordingly, the conclusion of
definitive documentation may be delayed or may not occur. For these reasons, among others, you should not place undue
reliance upon the Company’s forward looking statements. Except as required by law, the Company undertakes no obligation
to revise or update any forward looking statements in order to reflect any event or circumstance that may arise after the
date of this Report.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ORAMED PHARMACEUTICALS INC. |
|
|
|
|
By: |
/s/ Nadav Kidron |
|
Name: |
Nadav Kidron |
September 3, 2015 |
Title: |
President and CEO |
3
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Apr 2023 to Apr 2024